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Positive Surgical Margins in the 10 
Most Common Solid Cancers
Ryan K. Orosco  1, Viridiana J. Tapia1, Joseph A. Califano1,2,4, Bryan Clary2, Ezra E. W. Cohen4,5,  
Christopher Kane4,6, Scott M. Lippman4,5, Karen Messer4, Alfredo Molinolo4, James D. Murphy7,  
John Pang1, Assuntina Sacco4,5, Kathryn R. Tringale1, Anne Wallace2,4 & Quyen T. Nguyen1,2,3,4
A positive surgical margin (PSM) following cancer resection oftentimes necessitates adjuvant 
treatments and carries significant financial and prognostic implications. We sought to compare PSM 
rates for the ten most common solid cancers in the United States, and to assess trends over time. Over 
10 million patients were identified in the National Cancer Data Base from 1998–2012, and 6.5 million 
had surgical margin data. PSM rates were compared between two time periods, 1998–2002 and 2008–
2012. PSM was positively correlated with tumor category and grade. Ovarian and prostate cancers 
had the highest PSM prevalence in women and men, respectively. The highest PSM rates for cancers 
affecting both genders were seen for oral cavity tumors. PSM rates for breast cancer and lung and 
bronchus cancer in both men and women declined over the study period. PSM increases were seen for 
bladder, colon and rectum, and kidney and renal pelvis cancers. This large-scale analysis appraises the 
magnitude of PSM in the United States in order to focus future efforts on improving oncologic surgical 
care with the goal of optimizing value and improving patient outcomes.
One in four deaths in the United States (US) is due to cancer1. Treatment modalities vary considerably depending 
on stage and location, however surgical excision is an integral part of treatment for most solid tumors. The goal 
of surgical resection is the eradication of cancer-–both gross and microscopic. A positive surgical margin (PSM) 
occurs when this ideal is not achieved, and cancer cells are present at the edge of the resection specimen. The 
cancer biology, responses to neo-adjuvant and adjuvant therapies, and treatment paradigm differs across tumor 
types. Similarly, the impact that a PSM has on prognosis and treatment decisions depends on tumor type. For 
example, the 2017 National Comprehensive Cancer Network (NCCN) guidelines for kidney and ovarian cancer 
do not include surgical margins, but margins are mentioned 16 times in the oral cavity cancer guidelines. In gen-
eral, PSMs warrant additional (adjuvant) treatments, which confer significant increased costs and burden to the 
patient and healthcare system2.
To broadly characterize the scope of PSMs in surgical cancer care, we used today’s largest oncology database, 
the National Cancer Data Base (NCDB), to evaluate PSM prevalence in the ten most common solid organ cancers 
in the US.
Methods
The ten most common solid organ cancers in the US are: prostate, breast, lung and bronchus, colon and rectal, 
urinary bladder, thyroid, kidney and renal pelvis, uterine corpus, oral cavity, ovarian3. We included NCDB data 
(1998–2012) of patients with these cancers as their only malignancy (n = 10,400,589 Supplemental Table 1), and 
excluded patients: treated without surgery (n = 3,028,552), who underwent local tumor destruction (n = 98,450), 
with unknown surgery status (n = 62,071). Of the remaining 7,211,516 patients who underwent surgical resection 
of their cancer, surgical margin information was available for 6,495,889 (90.1%, Supplemental Table 1).
We examined the NCDB variable “margin status”, which represents presence or absence of tumor follow-
ing primary resection. PSM was defined as “microscopic residual tumor” (n = 311,635), “macroscopic residual 
tumor” (n = 48,871,) or “residual tumor, not otherwise specified (NOS)” (n = 214,675). Negative margins were 
defined as “no residual tumor” (n = 5,920,708). For patients undergoing multiple sequential surgeries, the NCDB 
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only reports the margin status of the final procedure, but does not specify which patients had multiple surgeries. 
Tumor (T) categories in the NCDB are based on the American Joint Committee on Cancer (AJCC) 6th and 7th 
editions.
PSM rates were determined for each cancer site by year, T category, gender, age group, and race. To assess 
PSM change over the study period, we compared PSM rates for the last 5 years (2008–2012) to the first 5 years 
(1998–2002), using the two-proportion z-test with pooled standard error. Additionally, we conducted a multi-
variable logistic regression to investigate the adjusted effect of these time periods on PSM. Patient-related covar-
iates included: gender, age, race/ethnicity, income, Charlson-Deyo4 comorbidity index (CI), and insurance type. 
Median household income, estimated by correlating postal code time of diagnosis with American Community 
Survey data, 2008–2012 and adjusted for inflation, was categorized by quartile (1st quartile < $38,000; 2nd 
$38,000–47,999; 3rd $48,000–62,999; 4th > $63,000). Tumor-related covariates included: tumor stage (T-stage) 
and histologic grade (American Joint Committee on Cancer (AJCC) seventh edition guidelines for pathologic 
staging5). Healthcare system covariates included: hospital tumor-specific case volume, facility type, and geo-
graphic location. Hospital tumor-specific volume was calculated using average number of cases reported to the 
NCDB per year (low volume < 25th percentile, high volume > 75th percentile). Facility type was based on CoC 
accreditation criteria. Statistical analyses were performed using STATA, version 13 (Stata, StataCorp LP, College 
Station, Texas).
The prognostic implications of PSM and accompanying adjuvant treatment considerations and costs were 
summarized. Adjuvant treatment recommendations were obtained from National Comprehensive Cancer 
Network (NCCN). This study was approved by the UCSD Institutional Review Board (protocol #150107). All 
methods were performed in accordance with relevant guidelines and regulations.
Disclosure. The American College of Surgeons and the CoC have not verified and are not responsible for 
the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.
Results and Discussion
Most patients were women (66.2%) and White (76.04%). There were 2,530,565 breast, 761,637 prostate, 241,791 
bladder, 1,218,834 colon and rectum, 314,459 thyroid, 120,826 oral cavity, 462,282 lung and bronchus, 361,240 
kidney and renal pelvis, 391,997 uterine, and 92,058 ovarian cases (Supplemental Table 1). There were 9.38% in 
situ, 43.25% T1, 20.04% T2, 13.74% T3, and 3.99% T4 cases. For each cancer site, PSM increased with higher 
tumor category and grade (Table 1).
PSM trends over time. Unadjusted PSM rates for breast, and lung and bronchus cancer in both men and 
women declined over the period of the study (Fig. 1A,B, Table 1). In contrast, PSM rates for bladder, colon and 
rectum, and kidney and renal pelvis increased for both genders. Ovarian cancer PSM rates decreased over time 
(Fig. 1A,B, Table 1).
Multivariable logistic regression analysis showed that patients treated in the second seven years (2006–2012) 
were more likely to have PSM for bladder (OR 1.09, p = 0.007) and kidney (OR 1.29, p < 0.0001) tumors, and less 
likely to have PSM for breast (OR 0.78, p < 0.0001), lung (OR 0.93, p = 0.002), and prostate (OR 0.96, p = 0.045) 
tumors (1998–2005) (Table 1). This means that a patient having surgery between 2006 and 2012 had a 22% lower 
chance of having a PSM than a patient treated during the 1998–2002 time period.
Clinical and financial impact PSM. The prognostic implications of PSM and accompanying adjuvant 
treatment considerations and costs are summarized in Table 2 for eight of the tumor sites—breast, prostate, blad-
der, colon and rectum, thyroid, oral cavity, lung and bronchus, uterine. The NCCN treatment guidelines for 
kidney and renal pelvis and ovarian cancers do not account for PSM, but a summary of corresponding PSM 
implications is provided in the manuscript text.
PSM for cancers affecting both genders. The highest PSM rates for cancers affecting both genders were 
oral cavity (12.75%), followed by thyroid cancers (11.52%). The greatest gender-specific difference in PSM rate 
was seen in bladder cancer (11.58% in women vs. 8.96% in men).
Breast cancer. Lumpectomy and mastectomy PSM rates were 6.58% and 5.30%, respectively (Table 1). PSM rates 
for lumpectomy is significantly lower than the reported national estimate of 22.9%5. This is likely due to NCDB’s 
practice of reporting final PSM, even if a patient has had multiple sequential procedures. Breast cancer patients 
may undergo multiple sequential lumpectomies, followed by mastectomy for persistent PSM.
Following mastectomy, PSM in node-negative disease is associated with an increased locoregional recur-
rence (LRR) and decreased disease-specific survival (DSS) (Table 2)6. In a meta-analysis, Moran et al. found that 
patients with close or PSM had 2-times greater odds of developing tumor recurrence than patients with negative 
margins7.
NCCN guidelines2 for patients with PSM is stratified by stage (Table 2). Patients with early-stage tumors are 
recommended to undergo re-excision, mastectomy; or for focal PSM without extensive intraductal component, 
a high chest wall irradiation boost. One in four women who undergo an attempt at breast-conserving therapy 
have positive or unclear margins and go on to have re-excision5,8. For patients with PSM after mastectomy, the 
NCCN recommends radiation to the chest wall, infraclavicular and supraclavicular regions, and potentially to 
the internal mammary nodes and any other part of the axillary bed at risk. These additional procedures confer 
increased discomfort and stress, increased risk of complications, potentially compromised aesthetic outcomes, 
and increased health care costs for both the patient and the healthcare system7,9–11.
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Oral Cavity cancer. The PSM rate for oral cavity cancer was 12.75% (Table 1)—the highest overall PSM rate for 
tumors affecting both genders. This finding is consistent with prior figures, although it is important to note that 
previously reports on PSM rates ranged widely (range 1–22%) and with some exceptions12, were derived primar-
ily from single-institution studies, and often included extra-oral sites13–16.
The prognostic implication of PSM in oral cavity cancer is significant. PSMs are independently associated with 
increased risk of LRR and decreased overall survival (OS) (Table 2)13–16. Sutton et al. reported a relative risk of 
death of 11.61 (p = 0.0013) for patients with PSM and 2.66 (p = 0.02) for patients with close margins, compared 
to those with negative margins17.
NCCN2 recommends that oral cavity cancer patients with PSM receive adjuvant therapy (Table 2), which is 
stratified based on stage. Early-stage patients (stage I-II) should undergo re-resection to obtain negative mar-
gins when feasible; otherwise they should receive radiation, or radiation with chemotherapy (for T2 tumors 
only). Locally advanced stage patients (stage III-IV, non-metastatic) should receive radiation with chemotherapy 
BREAST (LUMP, MAST, TOTAL) PROSTATE BLADDER
COLON & 
RECTUM THYROID
ORAL 
CAVITY
LUNG & 
BRONCHUS
KIDNEY 
& RENAL 
PELVIS UTERINE OVARIAN TOTAL
Number of 
Cases (n) 1,479,230 1,051,335 2,530,565 761,637 241,791 1,218,834 314,459 120,826 462,482 361,240 391,997 92,058 6,495,889
Number of PSM 
Cases 97,335 55,746 153,081 160,194 23,317 83,241 36,230 15,411 33,861 20,691 16,938 32,217 575,181
Overall PSM 
Rate (%) 6.58 5.30 6.05 21.03 9.64 6.83 11.52 12.75 7.32 5.73 4.32 35.00 8.85%
Gender
Men 8.30 4.47 5.53 21.03 8.96 6.71 13.24 12.65 8.00 6.04 N/A N/A 7.73% (109,572)a
Women 6.57 5.32 6.05 N/A 11.58 6.95 10.99 12.92 6.64 5.23 4.32 35.00 6.69% (256,260)a
Race
White 6.32 5.08 5.81 20.60 9.31 6.66 10.90 12.30 7.15 5.80 3.86 35.67 8.60% (424,725)
Black/AA 7.93 6.53 7.32 23.19 14.19 7.43 8.76 18.62 8.53 4.99 7.90 33.47 10.04% (58,393)
Other 7.28 5.68 6.57 22.21 9.20 7.12 15.32 13.62 7.46 5.82 4.78 27.81 9.34% (19,087)
Latino/Hisp 7.07 5.53 6.41 21.65 10.28 7.34 14.53 13.15 7.83 5.84 4.66 33.86 9.47% (72,976)
Age
<40 8.62 6.32 7.33 17.17 6.94 9.78 10.43 10.56 9.56 4.20 3.52 15.64 8.42% (28,867)
41–80 6.15 5.12 5.73 21.08 8.78 6.75 11.60 12.70 7.25 5.72 4.16 36.49 8.89% (494,280)
>81 10.18 6.14 8.45 17.07 13.41 6.68 23.78 14.09 7.79 7.10 6.78 42.76 8.74% (52,034)
T-category
In Situ 5.67 3.19 4.89 0.00 3.30 1.41 0.00 9.33 4.80 3.26 0.58 N/A 4.39% (26,766)
T1 5.63 3.74 4.99 19.02 6.24 2.74 5.21 7.85 3.05 2.87 1.00 3.94 5.96% (167,291)
T2 9.13 5.27 6.97 19.58 17.37 1.92 8.26 14.92 6.77 2.73 5.87 27.78 8.50% (110,683)
T3 20.11 9.55 11.05 45.95 24.07 5.61 24.79 20.32 19.57 14.17 25.70 58.25 11.26% (100,539)
T4 37.60 18.58 20.89 65.54 40.33 27.05 50.76 25.18 27.13 42.04 51.89 N/A 29.96% (77,740)
Grade
Well 
Differentiated 5.19 4.14 4.85 9.64 2.41 4.68 9.10 9.70 4.45 2.73 0.02 10.35
4.47% 
(44,669)
Mod 
Differentiated 6.66 5.23 6.07 15.99 4.75 5.82 19.52 13.81 6.32 3.61 2.53 25.98
7.51% 
(195,187)
Poorly 
Differentiated 7.21 5.94 6.59 27.31 14.47 12.47 32.77 18.61 8.71 8.44 10.77 45.22
13.11% 
(229,211)
Undifferentiated 8.45 6.95 7.76 31.51 16.26 15.54 61.89 20.57 9.91 16.28 15.58 48.31 16.46% (24,681)
Change over study period
Men −3.22**(−3.96:−2.47)
−0.213
(−0.44:0.02)
2.95**
(2.62:3.27)
2.41**
(2.25:2.56)
−0.775*
(−1.43:−0.12)
−0.252
(−0.83:0.33)
−0.374*
(−0.65:−0.10)
1.44**
(1.18–1.70) NA NA
Women −3.63**(−3.70:−3.55) NA
3.72**
(3.11:4.33)
2.38**
(2.23:2.54)
0.528*
(−0.12:0.19)
−1.15*v 
(−1.89:−0.41)
−0.74**
(−0.99:−0.49)
1.19**
(0.88:1.49)
0.481**
(0.33–0.64)
−4.59**
(−5.2:−3.97)
Table 1. Prevalence of PSM for individual tumor sites as a function of gender, race, age, tumor category, tumor grade. 
Analysis of PSM change over study period comparing unadjusted rate from the last 5 years of the study period 2008–
2012 to the first 5 years of the study period (1998–2002). a. Only tumors occurring in both genders are included here. 
b. Numbers given are percents unless otherwise indicated. *p < 0.05; **p < 0.001, Not applicable (NA).
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(category 1 recommendation), re-resection, or radiation alone. The need for adjuvant therapy–whether it be 
surgery, radiation, or radiation with chemotherapy–confers increased healthcare costs (Table 2) and subjects the 
patient to additional toxicities which can adversely impact quality of life18.
Bladder. PSM rate for bladder cancer was 9.64%, with women having higher PSM (11.58%) compared to men 
(8.56%) (Table 1). Our study is limited by NCDB coding which does not differentiate transurethral resection 
of bladder tumors from radical cystectomies. Thus, the PSM rates reported here reflect a combination of these 
two different procedures. Published PSM rates are divided based on presence or absence of muscle invasion, 
where non-muscle invasive refers to Ta, CIS or T1 tumor category, and muscle-invasive refers to all other tumor 
categories2. Based on a comprehensive literature review, Divrik et al. reported that the rates of residual tumor in 
non-muscle invasive bladder cancer after a transurethral resection of the bladder ranged from 28% to 74%19. In 
contrast, our study finds that non-muscle invasive tumors (Ta, CIS, T1) had a PSM rate of 6.24% at radical cystec-
tomy. For muscle-invasive bladder cancer, a 2010 multi-site study of 513 patients reported a 6.8% rate of PSM20, 
which is much lower than our PSM rates ranging from 17.37–40.33% (T-categories 2–4). This variability is likely 
due in part to differences in the underlying characteristics of the study populations, and to the inclusion of low 
and high volume centers in the NCDB.
Incomplete resection of bladder tumor, irrespective of muscle invasion has been associated with unfa-
vorable prognosis (Table 2). Studies of PSM in patients with non-muscle invasive cancer showed decreased 
recurrence-free survival. Dotan et al. examined the importance of margins in patients undergoing radical cys-
tectomy for muscle-invasive bladder cancer. They demonstrated that PSM had a profoundly negative impact on 
cancer specific survival, which decreased from 72% to 32% at 5 years. They also demonstrated that patients with 
PSM had a 3.5-fold increased risk (21% vs 6%) of local recurrence at 5 years, which is almost uniformly fatal. On 
multivariate analysis, PSM was an independent predictor of death from cancer21. The higher PSM rate for women 
may be due to the increased technical challenge of radical cystectomy and anterior exenteration in women which 
requires anterior vaginal dissection and hysterectomy and salpingo-oophorectomy.
NCCN2 recommends adjuvant radiotherapy or chemotherapy for patients with stage II margin positive dis-
ease (Table 2). Radical cystectomy is relatively contraindicated in patients with positive urethral margin, and 
chemoradiation is preferred22. Late stage bladder cancer requires higher radiotherapy boost2.
Colon and Rectum. The total PSM rate for colon and rectal cancer was 6.83%. Higher PSM rates correlated with 
higher T-category (Table 1), a finding consistent with prior reports23. For colon cancer, PSM is a poor prognostic 
feature for T2 and T3 tumors24. For rectal cancer, PSMs are considered a high-risk pathologic feature. In a Dutch 
study on rectal cancer, patients with PSM had a local recurrence rate of 22%, compared with 4% of those with 
negative margins25. Lin et al. also showed that when defining a PSM as less than 1 mm from the tumor, the rate 
of distant metastasis was 61.5%, compared with 15.2% for margins of >1 mm, making PSM a predictor for the 
development of distant metastasis26 and decreased disease-free survival27.
Based on NCCN guidelines2, PSM in colon cancer may warrant larger resection, chemotherapy, and consid-
eration for boost radiation (Table 2)2,27,28. For rectal cancers, PSM may mean larger resection with or without 
chemoradiation, and intra-operative radiation therapy (IORT) may be considered for PSM especially in T4 and 
recurrent cancers.
Kidney and Renal Pelvis. In this study, the PSM rate for patients with kidney and renal pelvis cancer was 5.73% 
(Table 1). Our data are similar to the literature review by Borghesi et al. in 2013, reporting that the overall incidence 
of PSMs after nephron-sparing surgery (NSS) when performed electively is quite low, ranging from 0% to 7%29. 
Comparable PSM rates have been reported between different surgical approaches: 0% to 7% in open partial 
Figure 1. Positive surgical margin (PSM) prevalence (reported as rate per 10,000 patients) for each cancer in 
women (A) and men (B) as a function of time.
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nephrectomy, 0.7% to 4% in laparoscopic partial nephrectomy (LPN), and 0.7% to 4% in robot-assisted partial 
nephrectomy30. Patients with an imperative indication for NSS seem to have a higher risk of PSM incidence 
(8.9–27.5%), likely due to the presence of larger tumors or unfavorable tumor location29,31.
There is no clear consensus on clinical implications of PSM in these cancers. Some authors have found limited 
influence on long-term oncological outcomes32, whereas others showed that PSM increased the hazard ratio of 
recurrence and metastasis33. Borghese et al. also reported that local recurrence seems to be more likely in patients 
with PSMs, especially in those with high-grade tumors29. NCCN guidelines for kidney and renal pelvis cancers 
do not account for PSM2.
BREAST PROSTATE BLADDER COLON & RECTUM
Prognostic 
Implications for PSM
Increased LRR, decreased 
DSS
Increased risk of 
biochemical recurrence; 
no impact on cancer-
specific mortality
Increased LRR, Decreased DSS Increased LRR and DM, decreased DFS and OS
Adjuvant Treatment 
Recommendations for 
PSM based on NCCN 
Guidelines
Early Stage
PSM after lumpectomy:
Re-excision
OR
Mastectomy
OR
Higher RT boost for focal 
PSM without extensive 
intraductal component
RT
Stage II (T2N0)
RT,
OR
Chemo (if no neoadjuvant therapy) 
Stage II (T2N0) primary urethra 
carcinoma (males):
Re-resection
Or
CRT (preferred)
Or
RT
Colon:
larger resection, T3N0M0 chemo,
and for any stage consider boost 
radiation
Late Stage
PSM after mastectomy:
Consider RT to chest 
wall +/− infraclavicular 
region +/− supraclavicular 
area +/− internal mammary 
nodes &any part of axillary 
bed at risk
RT Stage III-IV (T3–4, N0-2) urothelial:Higher RT boost
Rectum: larger resection, T1Nx after 
trans-anal excision:
Transabdominal resection +/− CRT
or CRT, and intra-operative radiation 
therapy (IORT) may be considered for 
PSM especially in T4 and recurrent 
cancers
Cost of Adjuvant 
Treatment due to PSM
Surgery
Lumpectomy alone: $70,520
Mastectomy alone: $48,258
Mastectomy + Recon: 
$88,089
Radiation RT: $8,600 RT: $18,000
Chemotherapy Chemo: $16,416 Chemo: $17,833
THYROID ORAL CAVITY LUNG & BRONCHUS UTERINE
Prognostic 
Implications for PSM No impact
Increased LRR, 
Decreased OS Decreased OS Potential increase in LRR
Adjuvant Treatment 
Recommendations for 
PSM based on NCCN 
guidelines
Early Stage
PSM after partial 
thyroidectomy (papillary): 
Completion thyroidectomy
STAGE I-II:
Re-resection
OR
RT
OR
CRT (T2 only)
STAGE IA:
Re-resection (preferred)
OR
RT (category 2B)
STAGE IB-IIA (node-negative):
Re-resection (preferred) +/− chemo
OR
RT +/− chemo (chemo for stage IIA)
STAGE IIA-B (node-positive):
Re-resection+ chemo
OR
CRT
Vaginal brachytherapy and/or RT for 
stage I after extrafascial hysterectomy
Late Stage
STAGE III-IV
CRT (category 1)
OR
Re-resection
OR RT
STAGE IIIA: CRT
T1, Nx rectal after trans-anal excision:
Transabdominal resection +/− CRT
OR
CRT
Cost of Adjuvant 
Treatment due to PSM
Surgery Surgery: $5,617 Surgery: $24,595 Surgery: $15,034
Radiation RT: $21,300 RT: $9,000 RT: $9066Brachytherapy: $7233
Chemotherapy Chemo + RT: $27,928
Table 2. Summary of the prognostic implications, adjuvant treatment recommendations, and associated cost 
estimates of PSM for individual tumor sites: breast, prostate, bladder, colon and rectum, thyroid, oral cavity, 
lung and bronchus, uterine. *Unless otherwise specified, recommendations are category 2 A (uniform NCCN 
consensus that intervention is appropriate based on lower-level evidence). Kidney and Ovarian excluded as 
surgical margin status does not affect adjuvant therapy recommendations. **Cost for adjuvant treatment was 
obtained from published data in the United States (listed in U.S. dollars) where available. NCCN: National 
Comprehensive Cancer Network, PSM: positive surgical margin, RT: radiation therapy; chemo: chemotherapy, 
CRT: chemoradiation; LRR: locoregional recurrence rate, DSS: disease-specific survival, DM: distant metastasis, 
DFS: disease-specific survival, OS: overall survival.
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Lung and Bronchus. We found an overall PSM rate of 7.32% for lung and bronchus cancers (Table 1), consistent 
with prior reports of PSM rates ranging from 6–7.8%34,35. Interestingly, we found higher PSM rates in young 
patients (<40 years). Previous work has shown that among young patients, male sex, non-adenocarcinoma his-
tology, black race, and main bronchial primary site are independent negative prognostic factors36.
Surgical resection plays a critical role in the treatment of lung cancer37, often providing the only potentially 
curative treatment for non-small cell lung cancer (NSCLC). However, clear surgical margins are difficult to 
obtain due to the limited amount of resectable tissue. Furthermore, the presence of occult micro-metastases are 
not uncommon38. Five-year OS following surgery for patients with stage I-III NSCLC is less than 50%39,40 and 
30–55% of NSCLC patients who undergo curative resection develop recurrence and die of their disease38. PSMs 
are associated with poor prognosis, significantly impact survival irrespective of stage37 and approximately halve 
the five-year survival rate41–43. Moving forward, tumor markers and intraoperative visualization may help better 
establish early- versus advanced-stage disease44–46.
NCCN (Table 2)2 recommends adjuvant treatment for PSMs based on stage11. Re-resection is typically pre-
ferred for early-stages with the option of concurrent chemotherapy, and alternatively, radiotherapy. For later 
stages, chemoradiotherapy is recommended as the preferred treatment in cases of PSM, which confers additional 
costs (Table 2).
Thyroid. Thyroid had one of the highest PSM rates (11.52%) of all cancers in this study (Table 1). This is com-
parable to a report of 10% PSMs from a retrospective study of patients with differentiated thyroid cancer47. Over 
the study period, the prevalence of PSM rates decreased in men, yet increased in women. This is interesting, par-
ticularly given less aggressive histologic subtypes are more common in women48. The highest PSM rate was seen 
in the elderly age group (23.78%).
Management of thyroid cancer is controversial due to the absence of high-level evidence regarding resection 
margins or adjuvant radiation therapy47,49. A large NCDB study showed that total thyroidectomy results in lower 
recurrence rates and higher survival for papillary thyroid cancer, when compared to lobectomy50. However, a 
more recent NCDB study did not observe a survival advantage with more extensive surgery51. Incomplete tumor 
resection has been recognized as one of the important poor prognostic factors in thyroid cancer patients who 
undergo total thyroidectomy52. American Thyroid Association has classified incomplete tumor resection as group 
at high-risk of recurrence53. In patients with non-invasive thyroid cancer, prior work has shown a significantly 
higher rate of early recurrence in the PSM group than the negative margin group—but all early recurrences were 
in regional lymph nodes of surgically non-dissected neck areas52. Disease-free survival has been shown to be 
impacted by PSM and extension of the tumor beyond the thyroid capsule54, prompting surgeons to weigh the pos-
sibility of impacting the functionality and quality of life of the patient against the aggressive surgical approaches 
that are more likely to completely clear tumor burden55,56.
NCCN2 recommends completion thyroidectomy for well-differentiated thyroid cancer with PSM (Table 2)57.
PSM for cancers affecting males only. Prostate. Prostate had the highest PSM rate (21.03%) of any 
cancer in men (Table 1). Reported PSM incidence for radical prostatectomy varies widely (4% to greater than 
48%)58,59. Yossepowitch et al. reported an average PSM rate in contemporary robot-assisted laparoscopic radical 
prostatectomy series of 15% (range 6.5–32%)60. Our multivariable analysis showed a notable prostate cancer PSM 
decrease between 2007–2012, which may be a result of more cancers being detected at earlier stages due to height-
ened PSA screening. Movement away from PSA screening since 2012 may reverse this trend.
Generally, urologic surgeons prioritize the preservation of as much of the neurovascular bundle as possible to 
prevent urinary incontinence and erectile dysfunction, thus precluding the execution of a wide surgical excision 
of periprostatic tissue and risking the occurrence of PSM61. Prostate cancer patients of advanced age were less 
likely to have PSM, indicating that most elderly patients likely underwent radical prostatectomy without nerve 
sparing, perhaps due to poorer pretreatment sexual function.
The clinical impact of PSM after radical prostatectomy has been studied extensively and there is a consensus 
that PSM is associated with a significantly increased risk of biochemical recurrence62–64. However, prior work has 
shown that neither single PSMs, nor multiple PSMs, post-radical prostatectomy were independent risk factors for 
metastases, castration-resistant prostate cancer, cancer-specific death, or all cause death in a cohort of patients 
who received early salvage radiotherapy upon biochemical recurrence64. While more aggressive tumor charac-
teristics have been identified as strong determinants for PSM, margin status was not an independent prognostic 
factor for survival65.
Per NCCN2, radiation therapy, either as adjuvant or early salvage therapy is indicated for PSMs to reduce the 
risk of biochemical recurrence (Table 2). The rapid adoption of new technologies for more targeted radiation such 
as intensity-modulated radiation has contributed to the increasing costs of radiation for prostate cancer, which is 
increasing faster than the costs of care for cardiovascular and pulmonary conditions66.
PSM for cancers affecting females only. Ovarian. Ovarian had the highest PSM rate among cancers 
affecting women (35.0%) and showed a significant decline over the study period (Table 1, Fig. 1A).
Patients with ovarian cancer are generally treated with a combination of surgery and adjuvant chemother-
apy. As mentioned previously, PSM is not part of the treatment paradigm for ovarian cancers2, as the surgical 
approach is focused on cytoreduction. Patients with newly-diagnosed, advanced ovarian cancer should have max-
imal surgical debulking to achieve minimal residual disease (residual implants < 1 cm).
Secondary debulking surgeries are potentially beneficial for patients who have an isolated relapse after a 
lengthy disease-free interval67. Studies have demonstrated that the volume of post-operatively residual disease 
inversely correlates with survival68–70. Interestingly, we found that PSM rates decreased over the study period on 
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univariable analysis. We hypothesize that this may be due to increased attention to the importance of reducing 
residual disease in cytoreductive surgeries71. However, this decrease was not noted in the multivariable logistic 
regression, likely due other confounding patient/tumor/institutional factors.
Ovarian had the highest PSM rate among cancers affecting women (35.0%). PSM for these cancers showed 
a significant decline over the study period on univariate, but not multivariate, analysis (Table 1, Fig. 1A). We 
hypothesize that this decline may be due to increased attention to the importance of reducing residual disease in 
cytoreductive surgeries70. However, the interpretation of PSM for this tumor type is unclear, and the implications 
of these ovarian NCDB data are limited. Other data sources with detailed cytoreductive information would con-
tribute to the surgical literature in a more relevant way.
Uterine. Uterine had the lowest PSM rate among cancers affecting women (4.32%). Elderly women, and patients 
with high stage and grade of uterine cancer, had higher PSM rates. PSM rates significantly increased throughout 
the study period (Table 1). To our knowledge, population-level PSM rates have not been reported in uterine 
cancer. The 26th Annual Report of the International Federation of Gynecology and Obstetrics (FIGO) states that 
83% of endometrial cancer patients are diagnosed and treated at early-stage (FIGO I and II)72,73. Surgery is the 
cornerstone of managing these early-stage patients.
The impact of PSM on clinical endpoints in endometrial cancer has been studied extensively. One study in Stage 
II endometrial cancer with extension into the cervix suggested that minimizing PSM at the cervical junction with 
an extended (radical) hysterectomy and removal of parametria should reduce LRR and possibly improve survival74. 
Additional work has shown an increased rate of local recurrence in patients undergoing extra-fascial hysterectomy 
as opposed to radical hysterectomy, presumably due to the reduction in positive surgical margins at the cervical 
junction75. Most recently, an NCDB study showed increased hazards for death among patients with PSMs76.
NCCN2 recommends adjuvant radiation77 for PSM after extrafascial hysterectomy in the case of invasive cer-
vical component (Table 2).
Limitations. This study is based on information from a national database, and lacks details about the criteria 
used to categorize margin status. There is no pathology information about how many millimeters the tumor 
was from the specimen edge. Additionally, the data set lacks information on number of resections or sequential 
procedures. Accordingly, the PSM prevalence reported here likely underestimates true PSM rates at the time of 
initial surgical resection.
Conclusion
This work serves to define the magnitude of PSM as a surgical challenge in the most common solid cancers in the 
US. Treatment algorithms vary considerably depending on cancer site and stage, but surgical excision remains 
axiomatic. A PSM commonly translates into worse prognosis and additional burden to patients and the health-
care system by necessitating adjuvant therapies. Our findings may be helpful to prioritize efforts aimed at mitigat-
ing PSM, thereby optimizing value and improving patient outcomes.
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